ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

trifarotene

Also written as “Trifarotene”, “Trifarotene Cream 0.005%” and “Trifarotene Cream”.

Its studies are mostly in Acne Vulgaris · Ichthyosis, Lamellar, led by 4 companies.

Drug pageTrifarotene: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 25, 202013 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Galderma Groupits history only91 open or runningphase 4since Jun 25, 2020Jun 8, 2012Dec 31, 2026phase 3 · NCT07186413
Sun Pharmaceutical Industries20 open or runningphase 1since Sep 20, 2023Sep 20, 2023none ahead
Mayne Pharma International Ptyits history only10 open or runningphase 2since Oct 24, 2018Oct 24, 2018none ahead
Teva Pharmaceutical Industriesits history only10 open or runningphase 3since Sep 19, 2022Sep 19, 2022none ahead

Also a collaborator on its studies: Teva Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sun Pharmaceutical Industries only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 20, 2023First study: phase 1 study in Acne VulgarisFirst studyNCT06063473 · 762 enrolled · United States
  2. Dec 10, 2024Phase 1 study in Acne VulgarisNCT06733402 · 1,000 enrolled · United States

TargetBeta

RARG →read by rule
“Retinoic acid receptor gamma agonist”ChEMBL 37, by rule

Other programs on RARG

ProgramCompanyFurthest phaseStudies
PalovaroteneruleIpsenphase 310

Studies

All 2 Sun Pharmaceutical Industries leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06733402Acne Vulgaris · United States1CompletedJun 20, 20241,000
NCT06063473Acne Vulgaris · United States1CompletedJul 13, 2023762

How it is read

Names in the registry

  • “Trifarotene”, 2 entries
  • “Trifarotene Cream 0.005%”, 2 entries
  • “Trifarotene Cream”, 2 entries
  • “Trifarotene 0.005 % Topical Cream”, 1 entry
  • “CD5789 Cream 200 µg/g”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.